-
1
-
-
33748684791
-
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment
-
Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF. 2006. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 58:714-722.
-
(2006)
J Antimicrob Chemother
, vol.58
, pp. 714-722
-
-
Aquaro, S.1
D'Arrigo, R.2
Svicher, V.3
Perri, G.D.4
Caputo, S.L.5
Visco-Comandini, U.6
Santoro, M.7
Bertoli, A.8
Mazzotta, F.9
Bonora, S.10
Tozzi, V.11
Bellagamba, R.12
Zaccarelli, M.13
Narciso, P.14
Antinori, A.15
Perno, C.F.16
-
2
-
-
33750338185
-
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir
-
Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 80:10794-10801.
-
(2006)
J Virol
, vol.80
, pp. 10794-10801
-
-
Baxter, J.D.1
Schapiro, J.M.2
Boucher, C.A.3
Kohlbrenner, V.M.4
Hall, D.B.5
Scherer, J.R.6
Mayers, D.L.7
-
3
-
-
0037804795
-
Expression of CD4 on human peripheral blood neutrophils
-
Biswas P, Mantelli B, Sica A, Malnati M, Panzeri C, Saccani A, Hasson H, Vecchi A, Saniabadi A, Lusso P, Lazzarin A, Beretta A. 2003. Expression of CD4 on human peripheral blood neutrophils. Blood 101:4452-4456.
-
(2003)
Blood
, vol.101
, pp. 4452-4456
-
-
Biswas, P.1
Mantelli, B.2
Sica, A.3
Malnati, M.4
Panzeri, C.5
Saccani, A.6
Hasson, H.7
Vecchi, A.8
Saniabadi, A.9
Lusso, P.10
Lazzarin, A.11
Beretta, A.12
-
4
-
-
33645034361
-
First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases
-
Bourgarit A, Lascoux C, Palmer P, Tuleja E, Pintado C, Farge D, Sereni D. 2006. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases. AIDS 20:471-473.
-
(2006)
AIDS
, vol.20
, pp. 471-473
-
-
Bourgarit, A.1
Lascoux, C.2
Palmer, P.3
Tuleja, E.4
Pintado, C.5
Farge, D.6
Sereni, D.7
-
5
-
-
0032505017
-
Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection
-
Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J. 1998. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12:1591-1600.
-
(1998)
AIDS
, vol.12
, pp. 1591-1600
-
-
Carotenuto, P.1
Looij, D.2
Keldermans, L.3
de Wolf, F.4
Goudsmit, J.5
-
6
-
-
0031575431
-
Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals
-
Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. 1997. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185:621-628.
-
(1997)
J Exp Med
, vol.185
, pp. 621-628
-
-
Connor, R.I.1
Sheridan, K.E.2
Ceradini, D.3
Choe, S.4
Landau, N.R.5
-
7
-
-
33846456210
-
Interruption of enfuvirtide in HIV-1-infected adults with incomplete viral suppression on an enfuvirtide-based regimen
-
Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR. 2007. Interruption of enfuvirtide in HIV-1-infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 195:387-391.
-
(2007)
J Infect Dis
, vol.195
, pp. 387-391
-
-
Deeks, S.G.1
Lu, J.2
Hoh, R.3
Neilands, T.B.4
Beatty, G.5
Huang, W.6
Liegler, T.7
Hunt, P.8
Martin, J.N.9
Kuritzkes, D.R.10
-
8
-
-
33144485618
-
CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients
-
Agence Nationale de Recherche sur le Sida PRIMO Study Group
-
Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, Delfraissy JF, Venet A, Rouzioux C, Morlat P, Agence Nationale de Recherche sur le Sida PRIMO Study Group. 2006. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42:709-715.
-
(2006)
Clin Infect Dis
, vol.42
, pp. 709-715
-
-
Goujard, C.1
Bonarek, M.2
Meyer, L.3
Bonnet, F.4
Chaix, M.L.5
Deveau, C.6
Sinet, M.7
Galimand, J.8
Delfraissy, J.F.9
Venet, A.10
Rouzioux, C.11
Morlat, P.12
-
9
-
-
33749021387
-
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
-
Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, Harrigan PR. 2006. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 3:e356.
-
(2006)
PLoS Med
, vol.3
-
-
Hogg, R.S.1
Bangsberg, D.R.2
Lima, V.D.3
Alexander, C.4
Bonner, S.5
Yip, B.6
Wood, E.7
Dong, W.W.8
Montaner, J.S.9
Harrigan, P.R.10
-
10
-
-
1642423935
-
HIV biological variability unveiled: Frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use
-
Karlsson I, Antonsson L, Shi Y, Karlsson A, Albert J, Leitner T, Olde B, Owman C, Fenyo EM. 2003. HIV biological variability unveiled: Frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 17:2561-2569.
-
(2003)
AIDS
, vol.17
, pp. 2561-2569
-
-
Karlsson, I.1
Antonsson, L.2
Shi, Y.3
Karlsson, A.4
Albert, J.5
Leitner, T.6
Olde, B.7
Owman, C.8
Fenyo, E.M.9
-
11
-
-
0038576281
-
-
Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-2185.
-
Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, TORO 1 Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-2185.
-
-
-
-
12
-
-
0042431969
-
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus
-
064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS
-
Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD, 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. 2003. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349:837-846.
-
(2003)
N Engl J Med
, vol.349
, pp. 837-846
-
-
Lawrence, J.1
Mayers, D.L.2
Hullsiek, K.H.3
Collins, G.4
Abrams, D.I.5
Reisler, R.B.6
Crane, L.R.7
Schmetter, B.S.8
Dionne, T.J.9
Saldanha, J.M.10
Jones, M.C.11
Baxter, J.D.12
-
13
-
-
0037849954
-
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
-
TORO 2 Study Group
-
Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, TORO 2 Study Group. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186-2195.
-
(2003)
N Engl J Med
, vol.348
, pp. 2186-2195
-
-
Lazzarin, A.1
Clotet, B.2
Cooper, D.3
Reynes, J.4
Arasteh, K.5
Nelson, M.6
Katlama, C.7
Stellbrink, H.J.8
Delfraissy, J.F.9
Lange, J.10
Huson, L.11
DeMasi, R.12
Wat, C.13
Delehanty, J.14
Drobnes, C.15
Salgo, M.16
-
14
-
-
33746160257
-
HIV-1 coreceptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response
-
Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. 2006. HIV-1 coreceptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 194:238-246.
-
(2006)
J Infect Dis
, vol.194
, pp. 238-246
-
-
Melby, T.1
Despirito, M.2
Demasi, R.3
Heilek-Snyder, G.4
Greenberg, M.L.5
Graham, N.6
-
15
-
-
33846455806
-
Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: Fitness tampering or a case of persistent braking on entering?
-
Morse C, Maldarelli F. 2007. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: Fitness tampering or a case of persistent braking on entering? J Infect Dis 195:318-321.
-
(2007)
J Infect Dis
, vol.195
, pp. 318-321
-
-
Morse, C.1
Maldarelli, F.2
-
16
-
-
0037119046
-
Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy
-
Mussini C, Pinti M, Borghi V, Nasi M, Amorico G, Monterastelli E, Moretti L, Troiano L, Esposito R, Cossarizza A. 2002. Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS 16:1609-1616.
-
(2002)
AIDS
, vol.16
, pp. 1609-1616
-
-
Mussini, C.1
Pinti, M.2
Borghi, V.3
Nasi, M.4
Amorico, G.5
Monterastelli, E.6
Moretti, L.7
Troiano, L.8
Esposito, R.9
Cossarizza, A.10
-
17
-
-
27944473910
-
-
Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. 2005. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 40:404-412.
-
Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. 2005. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 40:404-412.
-
-
-
-
18
-
-
33644834760
-
Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials
-
Raffi F, Katlama C, Saag M, Wilkinson M, Chung J, Smiley L, Salgo M. 2006. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 42:870-877.
-
(2006)
Clin Infect Dis
, vol.42
, pp. 870-877
-
-
Raffi, F.1
Katlama, C.2
Saag, M.3
Wilkinson, M.4
Chung, J.5
Smiley, L.6
Salgo, M.7
-
19
-
-
16244380203
-
Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization
-
Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. 2005. Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 79:4991-4999.
-
(2005)
J Virol
, vol.79
, pp. 4991-4999
-
-
Reeves, J.D.1
Lee, F.H.2
Miamidian, J.L.3
Jabara, C.B.4
Juntilla, M.M.5
Doms, R.W.6
-
20
-
-
20844452242
-
-
Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Sereni D, Viard JP, Delfraissy JF, Meyer L, SEROCO Cohort Study Group. 2005. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 192:46-55.
-
Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Sereni D, Viard JP, Delfraissy JF, Meyer L, SEROCO Cohort Study Group. 2005. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 192:46-55.
-
-
-
-
21
-
-
0025779332
-
Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children
-
Scarlatti G, Lombardi V, Plebani A, Principi N, Vegni C, Ferraris G, Bucceri A, Fenyo EM, Wigzell H, Rossi P, et al. 1991. Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. AIDS 5:1173-1178.
-
(1991)
AIDS
, vol.5
, pp. 1173-1178
-
-
Scarlatti, G.1
Lombardi, V.2
Plebani, A.3
Principi, N.4
Vegni, C.5
Ferraris, G.6
Bucceri, A.7
Fenyo, E.M.8
Wigzell, H.9
Rossi, P.10
-
22
-
-
0027440551
-
Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype
-
Scarlatti G, Hodara V, Rossi P, Muggiasca L, Bucceri A, Albert J, Fenyo EM. 1993. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology 197:624-629.
-
(1993)
Virology
, vol.197
, pp. 624-629
-
-
Scarlatti, G.1
Hodara, V.2
Rossi, P.3
Muggiasca, L.4
Bucceri, A.5
Albert, J.6
Fenyo, E.M.7
-
23
-
-
0030670330
-
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
-
Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyo EM, Lusso P. 1997. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3:1259-1265.
-
(1997)
Nat Med
, vol.3
, pp. 1259-1265
-
-
Scarlatti, G.1
Tresoldi, E.2
Bjorndal, A.3
Fredriksson, R.4
Colognesi, C.5
Deng, H.K.6
Malnati, M.S.7
Plebani, A.8
Siccardi, A.G.9
Littman, D.R.10
Fenyo, E.M.11
Lusso, P.12
-
24
-
-
33746146917
-
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: Recent data and consensus recommendations
-
Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, Dejesus E, Di Perri G, Estrada V, Fisher M, Kovacs C, Kulasegaram R, Lazzarin A, Marriott D, Muñoz L, Reynes J, Shalit P, Slim J, Tsoukas C, Vaccaro A, Vera J. 2006. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: Recent data and consensus recommendations. HIV Clin Trials 7:86-96.
-
(2006)
HIV Clin Trials
, vol.7
, pp. 86-96
-
-
Youle, M.1
Staszweski, S.2
Clotet, B.3
Arribas, J.R.4
Blaxhult, A.5
Carosi, G.6
Dejesus, E.7
Di Perri, G.8
Estrada, V.9
Fisher, M.10
Kovacs, C.11
Kulasegaram, R.12
Lazzarin, A.13
Marriott, D.14
Muñoz, L.15
Reynes, J.16
Shalit, P.17
Slim, J.18
Tsoukas, C.19
Vaccaro, A.20
Vera, J.21
more..
|